BioMarin Pharmaceutical Q1 2025 Update

Ticker: BMRN · Form: 10-Q · Filed: May 2, 2025 · CIK: 1048477

Biomarin Pharmaceutical INC 10-Q Filing Summary
FieldDetail
CompanyBiomarin Pharmaceutical INC (BMRN)
Form Type10-Q
Filed DateMay 2, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: pharmaceutical, earnings, 10-Q

Related Tickers: BMRN

TL;DR

BMRN Q1 2025 earnings are in, check the numbers for rare disease drug performance.

AI Summary

BioMarin Pharmaceutical Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's financial performance for the period is detailed in this 10-Q filing. Specific revenue figures, net income, and operational highlights for Q1 2025 are presented, alongside comparative data from Q1 2024.

Why It Matters

This filing provides investors with the latest financial and operational performance of BioMarin Pharmaceutical, crucial for understanding the company's trajectory in the rare disease drug market.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, BioMarin faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What were BioMarin's total revenues for the first quarter of 2025?

The filing indicates revenue data for the period ending March 31, 2025, and compares it to the period ending March 31, 2024, but specific dollar amounts for total revenue are not directly extracted in this header information.

What is BioMarin's primary industry classification?

BioMarin Pharmaceutical Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.

When is BioMarin's fiscal year end?

BioMarin's fiscal year ends on December 31.

What is the filing date of this 10-Q report?

This 10-Q report was filed on May 2, 2025.

Where is BioMarin Pharmaceutical Inc. headquartered?

BioMarin Pharmaceutical Inc. is headquartered in Novato, California.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 2, 2025 regarding BIOMARIN PHARMACEUTICAL INC (BMRN).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing